Accumulating evidence suggests that SEPP1 is downregulated and acts as a tumor suppressor in a variety of cancers, including prostate cancer, colorectal cancer (CRC), hepatocellular carcinoma (HCC) and gastric adenocarcinoma [11–15]. Here, SELENOP is linked to prostate carcinoma.